|
|
|
|
|
|
|
|
|
|
Blogger's Note: there is no clinical trial reference # in this article
UNM Health Sciences Center
Media Contacts
Michele Sequeira
In a new clinical trial Adams is treating women whose ovarian cancer results from mutated BRCA genes with a drug that kills the ovarian cancer cells and another that boosts the immune system in response to the dying cancer cells.
The clinical trial is currently open to women with BRCA1 or BRCA2 mutations who have a higher risk of getting breast and ovarian cancers and may have relatives who had these cancers at young ages.
In pre-clinical studies, this combination therapy eliminated tumors and helped mice to live longer. The clinical trial now makes the therapy available to women with BRCA gene mutations whose ovarian cancer has returned.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.